Medcura Overview
- Founded
-
2007
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$7.5M
- Investors
-
13
Medcura General Information
Description
Developer of wound care platform designed to be used across a broad spectrum of clinical and non-clinical setups for managing many high-impact surgical bleeds. The company's platform transforms highly abundant natural materials into advanced wound treatment and hemostatic products for surgical, military, and consumer applications, it develops Rapid-Seal, antibacterial barriers and a robust and diverse range of products that innovatively control bleeding, enabling doctors to improve bleeding management while creating antibacterial barriers and enhancing healing environments.
Contact Information
Website
www.medcurainc.com
Formerly Known As
Remedium Technologies, gel-e
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Primary Office
- 5650 Rivertech Court
- Suite S
- Riverdale, MD 20737
- United States
+1 (240) 000-0000
Medcura Timeline
Medcura Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC (Series A1) | 08-Sep-2022 | $7.5M | 000.00 | 000.00 | Completed | Generating Revenue |
| 13. Secondary Transaction - Private | 000.00 | Completed | Generating Revenue | |||
| 12. Secondary Transaction - Private | 01-Jun-2022 | 000.00 | Completed | Generating Revenue | ||
| 11. Later Stage VC | 01-Nov-2021 | 00.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 10. Later Stage VC (Series A) | 12-Aug-2021 | 00.00 | 0000 | 000.00 | Completed | Generating Revenue |
| 9. Later Stage VC (Series A) | 21-Sep-2020 | 00.000 | 00.000 | 0000 | Completed | Generating Revenue |
| 8. Angel (individual) | 31-Dec-2018 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 7. Grant | 01-Apr-2018 | 000 | 00.00 | Completed | Pre-Clinical Trials | |
| 6. Grant | 19-Feb-2018 | $1.4M | $3.1M | Completed | Generating Revenue | |
| 5. Seed Round | 13-Jul-2017 | $3.1M | $3.1M | 00.00 | Completed | Generating Revenue |
Medcura Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 000 | |
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Seed | 6,199,999 | $0.001000 | $0.5 | $0.5 | 1x | $0.5 | 18.85% |
Medcura Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of wound care platform designed to be used across a broad spectrum of clinical and non-clinical setups for man
Other Pharmaceuticals and Biotechnology
Riverdale, MD
19
As of 2023
000.00
00.00
0000-00-00
00000000000
000.00
000000
aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugia
0000000000000
Schlieren, Switzerland
00
As of 0000
000.00
000000000
000.00
000000
iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000000000000
Vancouver, Canada
00
As of 0000
000.00
000000 - 000
000.00
Add Comparison
Medcura Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InSphero | Formerly VC-backed | Schlieren, Switzerland | 00 | 000.00 | 000000000 | 000.00 |
| 000000 0000000000 | Venture Capital-Backed | Vancouver, Canada | 00 | 000.00 | 000000 - 000 | 000.00 |
| 0000000 000000000 | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000 00000000000 | Venture Capital-Backed | Middleton, WI | 00 | 0000 | 0000000000 0 | 0000 |
| 00000 0000000000 0 | Formerly PE-Backed | White Plains, NY | 000 | 000.00 | 000000&0 | 000.00 |
Medcura Patents
Medcura Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220347341-A1 | Hydrophobically-modified biopolymer materials | Pending | 03-Oct-2019 | 000000000 | |
| CA-3156813-A1 | Hydrophobically-modified biopolymer materials | Pending | 03-Oct-2019 | 000000000 | |
| CA-3135980-A1 | System and method to reduce tissue or organ adhesion | Pending | 05-Mar-2019 | 0000000000 | |
| EP-3934659-A1 | System and method to reduce tissue or organ adhesion | Pending | 05-Mar-2019 | 0000000000 | |
| EP-3934659-A4 | System and method to reduce tissue or organ adhesion | Pending | 05-Mar-2019 | A61K31/722 |
Medcura Executive Team (9)
Medcura Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| James Buck | Medcura | Chief Executive Officer, President & Board Member | 000 0000 |
| Larry Tiffany JD | Medcura | Co-Founder, Chief Operating Officer & Board Member | 000 0000 |
| Matthew Dowling Ph.D | Medcura | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
Medcura Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Medcura Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Ironwood Investment Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Aubrey Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Delaware Crossing Investor Group | Angel Group | 000 0000 | 000000 0 | ||
| New York Angels | Angel Group | Minority | 000 0000 | 000000 0 | |
| Sung Capital Partners | Family Office | Minority | 000 0000 | 000000 0 |